Therapeuticsmd, Inc.

Sancilio & Company, Inc.

Micelle Biopharma, Inc.

Other

Omega Biopharma, Inc.

Generx, Inc.

Frederick D Sancilio

Janice Louise Cacace

Thorsteinn Thorsteinsson

Julia M Amadio

Peter H R Persicaner

Brian A Bernick

Neda Irani

Peter Persicaner

Mohand Dahim

Annette M Shadiack

Jason D Legassie

Philip B Inskeep

Glynis Daniel-Archibald

Miguel Lopez-Toledano

Ahmed Abd Almalik Ahmed Mohammed Daak

Peter H Persicaner

Janice Cacace

Ahmed Abd Daak

Peter HR Persicaner

This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount.

Progesterone formulations having a desirable PK profile

Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.

Natural combination hormone replacement formulations and therapies

According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided. In various embodiments, such formulations are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.

Soluble estradiol capsule for vaginal insertion

According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.

Vaginal inserted estradiol pharmaceutical compositions and methods

Compositions including at least one Omega-3 fatty acid ester and at least one surface active agent are provided; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject such a composition, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. The compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Further provided are also various dosage forms for administering the compositions and use of the compositions in functional foods. Provided herein are also kits with instructions on how to administer the compositions.

Omega-3 fatty acid ester compositions

Progesterone formulations having a desirable pk profile

Compositions and methods for the solubilization of steroid hormones are disclosed.

Formulations for solubilizing hormones

Growing community of inventors

Palm Beach Gardens, FL, United States of America

Frederick D Sancilio